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 Short hairpin RNAs (shRNAs) efﬁciently inhibit gene expression by RNA interference. Here,
we report the efﬁcient inhibition by DNA-based vector-derived shRNAs of core protein expression in
Huh-7 cells. The shRNAs were designed to target the core region of the hepatitis C virus (HCV)
genome. The core region is the most conserved region in the HCV genome, making it an ideal
target for shRNAs. We identiﬁed an effective site on the core region for suppression of the HCV
core protein. The HCV core protein in core protein-expressing Huh-7 cells was downregulated by
core protein-shRNA expression vectors (core-shRNA-452, 479, and 503). Our results support the
feasibility of using shRNA-based gene therapy to inhibit HCV core protein production.
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INTRODUCTION
Hepatitis C virus (HCV) is one of the main causes of liver-related mor-
bidity and mortality. The virus establishes a persistent liver infection, leading
to the development of chronic hepatitis, liver cirrhosis, and hepatocellular
carcinomas. However, a highly effective anti-HCV drug has yet to be devel-
oped, due in part to the lack of detailed information about the HCV life
cycle.
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While aiming to develop an alternative treatment to interferons and fo-
cusing on gene therapy, we adopted a method of using RNA interference
(RNAi) based on short hairpin RNA (shRNA), which is expected to yield
good treatment effects as a therapeutic gene. As the target sequence, we
selected the HCV core protein gene.[1−4] Conservation of the core pro-
tein sequence is extremely high among HCV genes. Because HCV func-
tions as an mRNA and has a single strand genomic RNA, it is expected that
cleavage of the core protein mRNA will inhibit nuclear transport and virus
duplication.[5] We designed three shRNAs against the following regions of
the HCV core protein sequence: 452 to 472 nt, 479 to 499 nt, and 503 to
523 nt. We designed shRNA expression vectors targeting the core protein
site and compared their inhibitory effects.
MATERIALS AND METHODS
Plasmid Constructs
We designed DNA-based vectors expressing shRNA. Sense and antisense
strands of shRNA oligonucleotides were synthesized and then annealed
at 95◦C for 3 min, followed by slow cooling in phosphate buffered saline
(pH 7.4, containing 50 mM NaCl). These oligonucleotides contained the
loop CCACACC sequence. The annealed oligonucleotides were designed
to have KpnI and BamHI ends and these ends were inserted into the pU6
vector, which is based on pSV2-neo. A Pollll-type promoter was used for
shRNA expression. The constructed plasmids, pU6-core-shRNA-452, pU6-
core-shRNA-479, or pU6-core-shRNA-503, were used in the experiments.
The plasmids pU6-core-shRNA-452, pU6-core-shRNA-479, and pU6-core-
shRNA-503 were named to correspond with their respective targets in the
HCV core protein regions (452–472 nt, 479–499 nt, and 503–523 nt, respec-
tively). Scrambled shRNA (control) cloned into the same vector was used
as a negative control in all experiments. The inhibitory effects of the three
shRNAs were compared using a cell line produced by transducing the core
protein expression vector (pEF1-core) into Huh-7 cells.
Fluorescence Microscopy
To determine the intracellular localization of the transfected shRNA
expression vectors, Huh-7 cells (2 × 104 cells) were singly transfected or
cotransfected with pGFP-core (nuclear exporting vector), pDsRed-PA28γ,
and core-shRNA expression (pU6 plasmid) vectors, using the FuGENE 6
reagent according to the manufacturer’s protocol, and were cultured for 48
ha t3 7 ◦C in a 5% carbon dioxide atomosphere. Fluorescent cells were ex-
amined with a confocal microscope (Zeiss LSM5 PASCAL; Carl Zeiss, Jena,HCV Core Protein Suppression by shRNAs 817
Germany) at excitation wavelengths of 543 nm and 488 nm, using a 40×
objective. Images were acquired at a 512 × 512 resolution.
Chemiluminescent Enzyme Immunoassay
We determined the efﬁcacy of HCV core protein inhibition with the
pEF1-core protein vector (0.5 µg) transfected into Huh-7 cells. pEF1-core
protein vector (0.5 µg) and pU6-core shRNA (2 µg) were co-transfected
into Huh-7 cells using the FuGENE 6 transfection reagent. After 48 h, intra-
cellular HCV core protein was measured using an HCV core protein antigen
chemiluminescent enzyme immunoassay (CLEIA) assay. HCV core protein
FIGURE 1 Intracellular localization of triple-transfected expression vectors in Huh-7 cells. Plate-A:
Triple transfection of pU6-shRNA-452, pGFP-core (nuclear exporting vector), and pDsRed-PA28γ vec-
tors into Huh-7 cells. Cleavage of the GFP-core protein mRNA, which is the target of shRNA-452, gen-
erated expression only in the cytosol in the GFP image, while both the DsRed and merged images show
nuclear expression. Plate-B: Triple transfection of the pU6-shRNA-479, pGFP-core, and pDsRed-PA28γ
vectors into Huh-7 cells. Cleavage of GFP-core protein mRNA, which is the target of shRNA-479, gen-
erated expression only in the cytosol in the GFP image, while both the DsRed and the merged images
show nuclear expression. Plate-C: In a similar fashion, pU6-shRNA-503, together with pDsRed-PA28γ and
pGFP-core mRNA, expressed exhibited cytoplasmic localization in the GFP image. Plate-D: The scram-
bled version of all of the pU6-shRNAs was transfected with the pDsRed-PA28γ and pGFP-core vectors.
Nuclear expression is shown in the GFP, DsRed, and merged images.818 H. Suzuki et al.
antigen levels were determined using a fully automated CLEIA system ac-
cording to the manufacturer’s procedure.
RT-PCR
To determine the efﬁcacy of pU6-shRNA-mediated gene silencing, the
vectors were transiently transfected into HCV core protein-expressing Huh-
7 cells (4 × 104) using the FuGENE 6 transfection reagent according to the
manufacturer’s protocol.
The mRNA content was assessed by reverse transcriptase-polymerase
chain reaction (RT-PCR) at 48 h post-transfection and related to the amount
produced in the absence of pU6-shRNA.
RESULTS AND DISCUSSION
The expression of shRNAs targeting speciﬁc portions of the HCV core
protein in core protein-expressing Huh-7 cells is a critical factor for effec-
tive silencing. We conﬁrmed the inhibitory effect of the shRNA in the cells
using ﬂuorescence microscopy. The pGFP-core, pDsRed-PA28γ, and shRNA
expression vectors were simultaneously inserted into Huh-7 cells and the lo-
calization of the GFP-core was assessed by ﬂuorescence microscopy after a
48 h culture. The core proteins were localized in the cytoplasm of the core
protein-shRNA (core-shRNA-452, 479, and 503)-expressing Huh-7 cells. In
FIGURE 2 Inhibition of HCV replication by core protein-shRNAs in Huh-7 cells. The pEF1-core vector
(0.5 µg) and the pU6-core-shRNAs (2 µg) were co-transfected into Huh-7 cells (4 × 104). After 48 h,
the amount of intracellular HCV core protein was measured using the HCV core protein antigen CLEIA
assay.HCV Core Protein Suppression by shRNAs 819
FIGURE 3 Inhibition analysis of expressed HCV core protein mRNA by shRNA expression vectors using
an RT-PCR assay. The pEF1-core vector (0.5 µg) and pU6-core-shRNAs (2 µg) were co-transfected into
Huh-7 cells (4 × 104). After 48 h, total RNAs were extracted and subjected to RT-PCR.
the control cells (shRNA-scramble), the core proteins were localized in the
nucleus (Figure 1). This result indicates that the core protein-shRNA inhib-
ited the expression of the core proteins.
The inhibition of core protein production was then evaluated by CLEIA,
to determine whether the core proteins actually existed. The pEF1-core
and each of the shRNA expression vectors were co-transfected into Huh-
7 cells, and the cells were lysed and analyzed 48 h later. The results revealed
that core-shRNA-452, core-shRNA-479, and core-shRNA-503 inhibited the
expression of the HCV core protein (Figure 2). The inhibition mediated
by the core-shRNA-452 was much stronger than that of either core-shRNA-
479 or 503. In addition, the intracellular HCV core protein mRNA levels
were determined by RT-PCR. The pEF1-core and each of the shRNA ex-
pression vectors were co-transfected into Huh-7 cells. The presence of the
HCV core protein mRNA in the Huh-7 cells was examined by RT-PCR 48
h post-transfection. The shRNAs suppressed the expression of the core pro-
tein mRNA (Figure 3). Our study demonstrates that direct sequence-speciﬁc
degradation mediated by shRNA expression in the core protein-expressing
Huh-7 cells downregulates HCV core protein. Based on these results, shRNA
expression vectors targeted to the core region might be useful as anti-HCV
agents.
The results from this study support the potential use of shRNA expres-
sion vectors as a gene therapy approach to HCV replication, which might
prove to be a valuable means of treating HCV infections.
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